PT - 日刊文AU - Lenferink，安科AU - 范德Palen，工作AU - 范德瓦尔克，保罗D.L.P.M.AU - Cafarella，保罗AU - 维恩面包车，Anneke AU - 奎因，欧锦棠 - Groothuis - 奥茨胡恩，凯瑟琳娜G.M。AU - 伯特，莫顿G. AU - 年轻，玛丽AU - 弗里斯，彼得A. AU - 艾芬，塔尼娅W. TI - 加重行动计划COPD患者和合并症：一项随机对照试验AID - 10.1183 / 13993003.02134-2018 DP- 2019年11月1 TA - 欧洲呼吸杂志PG - 1802134 VI - 54 IP - 5 4099 - 4100 //www.qdcxjkg.com/content/54/5/1802134.short - //www.qdcxjkg.com/content/54/5/1802134.full SO - 欧洲呼吸J2019年11月1;54 AB - 这个国际随机对照试验评估是否COPD患者合并症，使用患者量身定制多疾病发作行动计划的培训，有较少COPD急性加重天，比常规护理（UC）.COPD患者（全球慢性阻塞性肺疾病（GOLD）分类II-IV）与≥1合并症（缺血性心脏疾病，心脏衰竭，糖尿病，焦虑症，抑郁症）被随机分配到患者定制的自管理干预组（n = 102）或UC（N = 99）。Daily symptom diaries were completed for 12 months. The primary outcome “COPD exacerbation days per patient per year” was assessed using intention-to-treat analyses.No significant difference was observed in the number of COPD exacerbation days per patient per year (self-management: median 9.6 (interquartile range (IQR) 0.7–31.1); UC: median 15.6 (IQR 3.0–40.3); incidence rate ratio (IRR) 0.87 (95% CI 0.54; 1.39); p=0.546). There was a significantly shorter duration per COPD exacerbation for self-management (self-management: median 8.1 (IQR 4.8–10.1) days; UC: median 9.5 (IQR 7.0–15.1) days; p=0.021), with no between-group differences in the total number of respiratory hospitalisations (IRR 0.76 (95% CI 0.42; 1.35); p=0.348), but a lower probability of ≥1 for respiratory-related hospitalisation compared to UC (relative risk 0.55 (95% CI 0.35; 0.87); p=0.008). No between-group differences were observed in all-cause hospitalisations (IRR 1.07 (95% CI 0.66; 1.72)) or mortality (self-management: n=4 (3.9%); UC: n=7 (7.1%); relative risk 0.55 (95% CI 0.17; 1.84)).Patient-tailored exacerbation action plans for COPD patients with comorbidities did not significantly reduce exacerbation days, but reduced the duration per COPD exacerbation and the risk of having at least one respiratory-related hospitalisation during follow-up, without excess all-cause mortality.Patient-tailored exacerbation action plans for COPD patients with comorbidities do not reduce exacerbation days, but reduce exacerbation duration and risk of having at least one respiratory-related hospitalisation during follow-up, without excess mortality http://bit.ly/2Mi8Fhc